The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.